August 7, 2020

This year's virtual, time-crunched Democratic National Convention isn't making space for many top Democrats to speak.

The DNC has set aside just two hours every night from August 17–20 for the convention where former Vice President Joe Biden will accept the nomination. That has led the Biden campaign to make some "ruthless cuts" to some of the highest profile Democrats out there, though the convention's official schedule is far from finalized, Politico reports.

"It goes without saying that the party's two most popular figures," former President Barack Obama and first lady Michelle Obama, will get a big role even with time so limited, Politico writes. Former President Bill Clinton and 2016 Democratic nominee Hillary Clinton are in as well. But some Democrats have "grumbled" that if Hillary Clinton is appearing, failed nominees like Al Gore and John Kerry probably should too, per Politico. Others are worried about "spotlighting" Bill Clinton "in the #MeToo era," Politico continues.

Rep. Alexandria Ocasio-Cortez (D-N.Y.) reportedly doesn't have a slot yet, nor do any of her fellow progressive political newcomers. But the party has reportedly made room for former Ohio Gov. John Kasich, a Republican who ran against President Trump in 2016. He'll speak on the same night as Sen. Bernie Sanders (I-Vt.) "in a demonstration of unity," Politico writes. Democrats are also reportedly on the lookout for veterans and Republicans with national security expertise to speak, though planning is still underway with just 10 days until the convention's first night. Read more about what to expect at the DNC at Politico. Kathryn Krawczyk

9:55 p.m.

A new Quinnipiac University poll released on Wednesday shows Sen. Lindsey Graham (R-S.C.) and Jaime Harrison, his Democratic challenger, tied at 48 percent among likely voters.

The survey also found that 48 percent of voters see Harrison in a favorable light compared to 43 percent who have a favorable opinion of Graham, and 51 percent of voters have an unfavorable view of Graham, compared to 35 percent who hold an unfavorable view of Harrison. Harrison is outspending Graham on advertisements and also bringing in more money from grassroots supporters, and Graham in turn has been making regular appearances on Fox News, asking viewers for money.

The race is also tight in the state between President Trump and Democratic presidential nominee Joe Biden, with Trump leading Biden by one point, 48 to 47 percent. Trump easily won South Carolina in 2016, with 54.9 percent of the vote, about 14 points ahead of Hillary Clinton.

The survey was conducted from Sept. 23 to 27, with 1,123 likely voters polled. The margin of error is plus or minus 2.9 percentage points. Catherine Garcia

8:34 p.m.

Centers for Disease Control and Prevention Director Robert Redfield wanted to extend the agency's No Sail Order for cruise ships set to expire on Wednesday, but was blocked by the White House, The New York Times reports.

At the beginning of the pandemic, there were several coronavirus outbreaks on cruise ships; the Diamond Princess, for example, saw 700 of its 3,711 passengers and crew members test positive for COVID-19, with 14 dying. Wanting to avoid a repeat of this, Redfield argued the No Sail Order, which went into effect in April as a way of combating the coronavirus, should be extended until mid-February 2021, but he was overruled during a White House Coronavirus Task Force meeting on Tuesday, the Times reports. The task force decided instead ships will be able to set sail after Oct. 31.

The Cruise Lines International Association says the industry generates $53 billion in economic activity every year, and its biggest market in the United States is Florida. Republican politicians in the swing state and cruise industry lobbyists have been arguing that the No Sail Order should not be extended, but White House Deputy Press Secretary Brian Morgenstern told the Times the task force's decision was not politically motivated.

"The president, the vice president, and the task force follow the science and data to implement policies that protect the public health and also facilitate the safe reopening of our country," he said. Catherine Garcia

7:02 p.m.

On Wednesday, six rockets landed near Erbil International Airport in northern Iraq's semiautonomous Kurdistan region, the Ministry of Interior of the Kurdistan Regional Government announced, and a U.S. defense official told CNN there are initial indications that three of the rockets hit a base housing U.S. troops.

There are no reports of U.S. injuries, CNN reports, but the official called the attack "troubling" because of the number of rockets fired and the possibility that several of the rockets were larger than those typically used.

The Ministry of Interior said the rockets were fired from the direction of Sheikh Amir, a town in Nineveh province that is controlled by Hashad al Shabbi, a predominantly Shia paramilitary force.

Prime Minister of Kurdistan Region of Iraq Masrour Barzani tweeted that "the KRG will not tolerate any attempt to undermine Kurdistan's stability and our response will be robust. I have spoken to the Prime Minister of Iraq, Mustafa al-Kadhimi, on the importance of holding the perpetrators accountable." Catherine Garcia

5:57 p.m.

The NBA Finals are always high stakes, but there are several storylines behind the seven game series between the Los Angeles Lakers and Miami Heat that tips off Wednesday night that could turn it into a particularly memorable showdown.

Friends-turned-nemeses — LeBron James will don the Lakers purple and gold against the Heat, whom he helped lead to back-to-back titles during his four-year stint in South Beach that ended in 2014. James' decision to leave the Heat and return to the Cleveland Cavaliers, who drafted him 2003, was received warmly around the league and paid off when he won he brought a ring to Ohio in 2016, but Miami fans still have a sour taste in their mouths, and James' relationship with Heat president, Pat Riley, has reportedly diminished after the abrupt departure. James has downplayed the personal aspect of the series, but there is history there.

It's about time — Most franchises wouldn't be too concerned about a 10-year gap between Finals appearances, but the Lakers are different. They've been to 32 Finals throughout their history, the most of any team in the NBA, but it's been a decade since they made it this far and won their last championship behind the late Kobe Bryant, whose presence will certainly loom over the series.

Legacies — Any postseason series James plays in at this point in his Hall of Fame career has an affect on his legacy, but securing another ring would go a long way. James has made nine of the last 10 NBA finals, including this year's, but some of his critics still knock him for going 3-6 in his previous appearances. A title would also likely throw James' co-star Anthony Davis into a conversation about the best big men of all time. On the Miami side, Erik Spoelstra is continuing to cement himself as one of the league's great coaches, and their leader Jimmy Butler is trying to establish that he's capable of being the centerpiece on a title-winning team. Tim O'Donnell

5:27 p.m.

Another study is warning against President Trump's debunked coronavirus treatment.

Despite being studied as an early coronavirus treatment, studies have found the malaria drug hydroxychloroquine ineffective and even dangerous when used to fight coronavirus. A study published Wednesday added to that evidence, finding that the drug was ineffective in preventing health care workers from contracting coronavirus.

For the study published in JAMA Internal Medicine, researchers at the University of Pennsylvania focused on 125 health care workers. Some of them received hydroxychloroquine for eight weeks from April to July, while others got a placebo. Throughout that time, four of the 64 workers who got the drug ended up with COVID-19, while four of the 61 who got the placebo did as well. Six of those who tested positive developed coronavirus symptoms, but none needed to be hospitalized. As a result, the researchers said they "cannot recommend the routine use of hydroxychloroquine" to prevent infections among health care workers.

In June, a clinical trial published in the New England Journal of Medicine also showed hydroxychloroquine wasn't effective in preventing coronavirus infections after exposure to the virus. The FDA has since removed its emergency use authorization for the drug as a coronavirus treatment, and in July it released a study showing how the drug could cause serious side effects in hospitalized patients. Kathryn Krawczyk

5:03 p.m.

Fox News' Chris Wallace received mixed reviews for his performance as the moderator for the first 2020 presidential debate. Some analysts blamed him for failing to keep things under control, while others believe he did the best he could. For his part, Wallace said he's "just sad with the way" it all turned out.

In an interview with The New York Times, Wallace spoke candidly about the situation, admitting that he felt desperate while trying to prevent the candidates from interrupting each other. He also said he didn't realize until it was too late that President Trump wasn't planning to stop ignoring the ground rules (Wallace refused to say whether Trump deserved the primary blame for how things unfolded). "I never dreamt that it would go off the tracks the way it did," he told the Times, adding that, despite his lengthy journalism career, "I've never been through anything like this."

Afterwards, Wallace had no desire to celebrate, though he did reluctantly accept a glass of champagne from his producers at the airport. He said he's "been involved in a certain amount of soul-searching" since returning home. Read more at The New York Times. Tim O'Donnell

4:51 p.m.

Rep. Katie Porter (D-Calif.) never wastes an opportunity to roast a CEO.

On Wednesday, three pharmaceutical executives, including former Celgene CEO Mark Alles, testified on drug pricing for the House Oversight Committee. While at the company, Alles saw a massive increase in the price of the cancer drug Revlimid — and Porter broke down just what it got Alles in return.

Porter started her takedown by asking Alles if he knew what a Revlimid pill cost in 2005: $215, she reminded him with the help of a whiteboard. And by the time Alles left the company late last year, after its sale to Bristol-Myers Squibb, a single Revlimid pill cost $763. "Did the drug get substantially more effective in that time? Did cancer patients need fewer pills?" Porter questioned, trying to figure out why Celgene upped the price. Alles answered by saying Revlimid proved effective in more patients. "So you discovered more patients who might benefit from paying $763 a pill?" Porter rhetorically responded, outlining how the average senior in her district couldn't even afford one pill.

Porter then moved on to tear apart the $13 million Alles made in 2017 as Celgene's CEO. "It's 200 times the average American's income and 360 times what the average senior makes on Social Security," Porter noted. She then reminded Alles just how he made "half a million dollars, personally, just by tripling the price of Revlimid." "The drug didn't get any better, the cancer patients didn't get any better, you just got better at making money," Porter concluded. Watch her questioning below. Kathryn Krawczyk

See More Speed Reads